PDEX
Pro-Dex, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Last price
65.67
▼ 0.64 (0.97%)
MARKET · —
Price
Open
66.30
Prev close
66.31
Day high
66.33
Day low
64.59
Volume
26.82K
Market cap
$209.67M
P/E (TTM)
18.09
52W range
23.47 – 69.86
Trailing performance
Returnvs SPY
1W
-2.01%
-0.6%
1M
+20.12%
+16.4%
3M
+4.89%
+1.8%
6M
+66.17%
+55.1%
YTD
+70.66%
+58.4%
1Y
+46.78%
+26.8%
3Y
+302.39%
+228.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$209.67M
Enterprise value$218.86M
Revenue (TTM)$74.64M
Gross profit$20.73M
EBITDA$12.11M
Net income$12.00M
EPS (TTM)$3.63
Free cash flow$5.40M
Total cash$10.98M
Total debt$20.17M
Book value / share$14.14
Shares outstanding3.19M
Float1.73M
Short % of float23.77%
Dividend yield—
Beta (5Y)0.05
Valuation & profitability ratios
Trailing P/E18.09
Forward P/E31.88
PEG ratio—
Price / sales—
Price / book4.64
EV / revenue2.93
EV / EBITDA18.08
Gross margin27.78%
Operating margin15.51%
Profit margin16.08%
Return on equity29.83%
Return on assets9.70%
Debt / equity44.63
Current ratio3.67
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $66.59M | $53.84M | $46.09M | $42.04M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $8.98M | $2.13M | $7.07M | $3.85M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | $8.98M | $2.13M | $7.07M | $3.85M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Mar 2026 | — | 1.20 | — |
| Sep 2025 | 0.50 | 1.40 | +180.0% |
| Jun 2025 | 0.47 | 0.36 | -23.4% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $19.20M | +9.8% |
| Next quarter | — | — | $19.60M | +5.8% |
| Current year | — | — | $76.40M | +14.7% |
| Next year | — | — | $81.00M | +6.0% |
Analyst targets & ownership
Mean target$70.00
High target$70.00
Low target$70.00
Implied upside6.59%
Analyst count1
ConsensusNONE
Strong buy / Buy0 / 1
Hold0
Sell / Strong sell0 / 0
Held by insiders37.08%
Held by institutions31.85%
Institutions holding106
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
+21.42K
Net buying
Buy transactions
4
32.42K shares
Sell transactions
2
11.00K shares
Net transactions
+6
Buys less sells
Sell : buy shares
0.3 : 1
Mixed
Insider-held shares
1.18M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 23, 26 | DOMINGO ANGELITA REBAMONTAN Director |
STOCK | 19 | $1.04K | Direct |
| Jul 1, 26 | CHARLTON ALISHA K Chief Financial Officer |
STOCK | 10.80K | $0 | Direct |
| Jul 1, 26 | VAN KIRK RICHARD LEE JR Chief Executive Officer |
STOCK | 14.80K | $0 | Direct |
| Jul 1, 26 | DOMINGO ANGELITA REBAMONTAN Director |
STOCK | 6.80K | $0 | Direct |
| May 22, 26 | VAN KIRK RICHARD LEE JR Chief Executive Officer |
SELL | 10.00K | $626.25K | Direct |
| Mar 16, 26 | DOMINGO ANGELITA REBAMONTAN Director |
SELL | 998 | $47.15K | Direct |
| Jan 22, 26 | DOMINGO ANGELITA REBAMONTAN Director |
STOCK | 18 | $618 | Direct |
| Nov 21, 25 | PHILP KATRINA MARIE KRAMER Director |
STOCK | 3.10K | $101.40K | |
| Nov 20, 25 | CABILLOT RAYMOND E Director and Beneficial Owner of more than 10% of a Class of Security |
STOCK | 1.00K | $0 | Direct |
| Nov 20, 25 | HOVDA DAVID C Director |
STOCK | 1.00K | $0 | Direct |
| Nov 20, 25 | CHARLTON ALISHA K Chief Financial Officer |
STOCK | 1.00K | $0 | Direct |
| Nov 20, 25 | SWENSON NICHOLAS JOHN Director and Beneficial Owner of more than 10% of a Class of Security |
STOCK | 1.00K | $0 | Direct |
| Nov 20, 25 | FARRELL WILLIAM JAMES III Director |
STOCK | 1.00K | $0 | Direct |
| Nov 20, 25 | PHILP KATRINA MARIE KRAMER Director |
STOCK | 1.00K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CABILLOT RAYMOND E |
Director and Beneficial Owner of more than 10% of a Class of Security | 272.85K | Stock Award(Grant) |
CHARLTON ALISHA K |
Chief Financial Officer | 24.17K | Stock Award(Grant) |
DOMINGO ANGELITA REBAMONTAN |
Director | 18.80K | Stock Award(Grant) |
FARRELL WILLIAM JAMES III |
Director | 7.10K | Stock Award(Grant) |
HOVDA DAVID C |
Director | 4.30K | Stock Award(Grant) |
PHILP KATRINA MARIE KRAMER |
Director | — | Stock Award(Grant) |
SWENSON NICHOLAS JOHN |
Director and Beneficial Owner of more than 10% of a Class of Security | 1.02M | Stock Award(Grant) |
VAN KIRK RICHARD LEE JR |
Chief Executive Officer | 99.23K | Stock Award(Grant) |
Moving averages & technicals
SMA 10
66.83
-1.73% from price
SMA 20
64.07
+2.50% from price
SMA 50
61.79
+6.28% from price
SMA 100
59.28
+10.77% from price
SMA 200
49.96
+31.44% from price
EMA 12
65.79
-0.18% from price
EMA 26
63.92
+2.73% from price
EMA 50
62.13
+5.69% from price
RSI (14)
56.1
Neutral
MACD (12,26,9)
1.87
Hist 0.04
ATR (14)
3.42
5.21% of price
Realised vol 30D
51.6%
Annualised
Bollinger upper
72.83
20, 2σ
Bollinger lower
55.30
20, 2σ
50 / 200 cross
Golden
61.79 vs 49.96
Trend bias
Above 200
+31.44%
Risk profile
Beta vs SPY
1.09
More volatile than market
Correlation to SPY
0.23
Largely independent
Realised vol 30D
51.6%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-50.2%
Peak to trough
Max drawdown 5Y
-65.3%
Peak to trough
ATR 14
3.42
5.21% of price
Beta (reported)
0.05
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
Vivos Therapeutics, Inc. (VVOS) Reports Q2 Loss, Lags Revenue Estimates
Zacks · 8d ago
Aveanna Healthcare (AVAH) Beats Q2 Earnings and Revenue Estimates
Zacks · 9d ago
Pro-Dex Inc (PDEX) Positioned to Strengthen with Zimmer’s mBos Robot Commercialization
Insider Monkey · 12d ago
Dentsply International (XRAY) Beats Q2 Earnings and Revenue Estimates
Zacks · 16d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.